Client Overview

Large global pharmaceutical company with well-established pipeline working in rare diseases.

Timeframe: One-year

Project Objective

Support secretariat for roundtable discussions with KOLs, patient advocates, and multiple company sponsors, as well as development of policy white paper and European Union (EU) parliament launch.

Challenges

Preparing crowded, cost-constrained market for new therapy to be launched in the EU.

Objectives

Support patient groups’ capacity in their quest to heighten policy maker awareness of need for development and availability of new treatments.

Key Strategies Implemented

1

Convened multi-stakeholder roundtable to address unmet patient needs.

2

Wrote patient-focused policy brief and call to action.

3

Launched policy brief in European Parliament with MEP sponsorship and participation.

4

Secured professional society endorsements.

5

Publicized and distributed policy brief and call to action.

6

Ensured inclusion of recommendations in key European Union programs, e.g., Horizon 2020, Health for Growth Programme.

7

Built patient group capacity through policy monitoring counsel and staff training.

Testimonial

"The recommendations coming from the roundtable and white paper will have a significant impact on progressing treatment choice." Mid-large-size Biopharmaceutical Company

The Outcome

short-term

Short Term

Policy brief and outreach activities enhanced policy decision-maker awareness of need for research, and new treatments.

long-term

Long Term

Established durable platform for continued policy maker education and advocacy.

key-highlights

Key Highlights

Successful white paper launch in EU parliament.